List view / Grid view
Multiomics, AI and liquid biopsies are giving researchers real-time insight into tumour biology and enabling more personalised cancer therapies. Find out how these technologies are advancing biomarker discovery, improving patient stratification, and guiding the design of new treatments.
Find out how dual-target ADCs and tumour-specific Treg depletion are shaping the next wave of targeted cancer therapies.
From first-in-human trial results to emerging AI tools and patient-focused innovations, AACR 2025 offered a clear snapshot of where cancer research is heading. Drug Target Review was on the ground in Chicago to explore the clinical data, technologies, and conversations shaping cancer drug development.
DTR speaks with Dr Patrick van Berkel at ADC Therapeutics to discuss how the company is transforming exatecan delivery to achieve better health outcomes.
CAR-T therapy has shown effectiveness in cancer treatment, but relapse often occurs due to limited cell persistence. New strategies aim to improve CAR T-cell durability for longer lasting remission.
Recent advancements in targeted therapies and immunotherapies are transforming lung cancer treatment. Discover how these innovations are improving outcomes and providing hope for patients.
Dr Richard Cote and Dr Ramaswamy Govindan of the Washington University School of Medicine elucidate how AI, particularly deep learning networks, could identify histopathologic features in non-small cell lung cancer, and impact the treatment approach for early-stage patients.
Founder and CSO of Achilles Therapeutics Dr Sergio Quezada reveals how the landmark TRACERx study has gleaned key insights that could make the difference between success and failure in immunotherapy treatment.
US researchers found high levels of XBP1s in lung cancer cells, which plays a key part in regulating the local immune environment in lung tumours, and can be disabled to increase anti-cancer immunity
In this article, Dr Jens Bjørheim, Chief Medical Officer of Ultimovacs, explains why vaccination has proved the best strategy to target human telomerase and why this complex may be an effective approach to combat cancer.
Researchers have discovered that in mice with cancers in the liver, immunotherapy and radiotherapy prevented T-cell death.
A new study has suggested that the enzyme GFPT2 could be a useful target for non-small cell lung cancer (NSCLC).
According to the study, the transcription factor IRF4 drives T cell differentiation and immunosuppression in multiple human cancers.
Researchers have slowed the spread of a type of non-small cell lung cancer in mice by neutralising a protein that would otherwise cause tumour growth.
A novel CDK8 inhibitor has been developed by scientists at Ryvu Therapeutics. Dr Krzysztof Brzozka showcases this molecule and explains the R&D behind it.
